Casadei Gardini Andrea Ricercatore a tempo determinatoMedicinaMED/06

Ricercatore senior di Oncologia presso Università Vita-Salute San Raffaele, Istituto Scientifico San Raffaele, Milano

POSIZIONI PREGRESSE E TITOLI

• Laurea in Medicina e Chirurgia presso l’Università di Bologna (2008).
• Specializzazione in Oncologia Medica presso l’Università di Ferrara (2014).
• Dirigente medico dal 2014 al 2018 presso il dipartimento di oncologia medica dell’Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS
• Fellowship dal 27/03/2017 fino al 27/12/2017 presso la Clinica Universidad de Navarra, Unita di epatologia, Pamplona, Spagna.
• Da dicembre 2018 a settembre 2020 ricercatore senior presso l’università di Modena e Reggio Emilia.
• Abilitazione scientifica nazionale di seconda fascia settore concorsuale 06/D3- Malattie del sangue, oncologia e reumatologia ottenuta in data 21/01/2020.

ATTIVITA’ ASSISTENZIALI E DI RICERCA

Le attività assistenziali e di ricerca si concentrano principalmente sulla diagnosi e trattamento della patologia oncologica epatobiliare (epatocarcinoma e colangiocarcinoma).

L’attività scientifica si svolge anche attraverso progetti di studi clinici e traslazionali collaborativi internazionali multi-istituzionali – europei e statunitensi.

Autore e coautore di 130 pubblicazioni su riviste internazionali.

Vincitore di diversi bandi italiani e spagnoli su studi clinici e traslazionali sulle patologie epatiche primitive.

Relatore a congressi nazionali ed internazionali.

Revisore scientifico e editor di diverse riviste oncologiche.

Estensore linee guida Associazione Italiana Oncologia Medica sull’epatocarcinoma (2017-presente):

Identificatore univoco del ricercatore:  
https://www.scopus.com/authid/detail.uri?authorId=57205570340
https://pubmed.ncbi.nlm.nih.gov/?term=casadei+gardini&sort=date

https://www.linkedin.com/in/andrea-casadei-gardini-229255156/?originalSubdomain=it

 

1: Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani

S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu

A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini

A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma

patients: Too early or too fast? Crit Rev Oncol Hematol. 2020 Nov 12;157:103167.

doi: 10.1016/j.critrevonc.2020.103167. Epub ahead of print. PMID: 33271389.

 

2: Pretta A, Ziranu P, Puzzoni M, Lai E, Orsi G, Liscia N, Molinaro E, Mariani

S, Riggi L, Rovesti G, Dubois M, Migliari M, Persano M, Saba G, Impera V, Musio

F, Batzella E, Demurtas L, Pusceddu V, Astara G, Faloppi L, Casadei Gardini A,

Andrikou K, Cascinu S, Scartozzi M. Retrospective survival analysis in patients

with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2

diabetes mellitus. Tumori. 2020 Nov 26:300891620976945. doi:

10.1177/0300891620976945. Epub ahead of print. PMID: 33243068.

 

3: Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría

E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P,

Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ,

Iraburu MJ, Chen C, Sangro B, Marin JJ, Martinez-Chantar ML, Banales JM, Arnes

R, Huch M, Patino J, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero

FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Dual targeting of

G9a and DNMT1 for the treatment of experimental cholangiocarcinoma. Hepatology.

2020 Nov 22. doi: 10.1002/hep.31642. Epub ahead of print. PMID: 33222246.

 

4: Molinaro E, Andrikou K, Casadei-Gardini A, Rovesti G. BRCA in

Gastrointestinal Cancers: Current Treatments and Future Perspectives. Cancers

(Basel). 2020 Nov 12;12(11):3346. doi: 10.3390/cancers12113346. PMID: 33198203;

PMCID: PMC7697442.

 

5: Casadei-Gardini A, Rovesti G, Dadduzio V, Vivaldi C, Lai E, Lonardi S,

Fornaro L, Pretta A, Zagonel V, Bernardini L, Astara G, D'Amico FE, Masi G,

Rimini M, Scartozzi M, Cascinu S. Impact of Aspirin on clinical outcome in

advanced HCC patients receiving sorafenib and regorafenib. HPB (Oxford). 2020

Nov 12:S1365-182X(20)31183-7. doi: 10.1016/j.hpb.2020.09.024. Epub ahead of

print. PMID: 33191108.

 

6: Pelizzaro F, Penzo B, Peserico G, Imondi A, Sartori A, Vitale A, Cillo U,

Giannini EG, Forgione A, Ludovico Rapaccini G, Di Marco M, Caturelli E, Zoli M,

Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni

G, Giuseppe Foschi F, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F,

Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA)

group. Monofocal hepatocellular carcinoma: How much does size matter? Liver Int.

2020 Nov 6. doi: 10.1111/liv.14718. Epub ahead of print. PMID: 33155401.

 

7: Rimini M, Rovesti G, Casadei-Gardini A. Child Pugh and ALBI grade: past,

present or future? Ann Transl Med. 2020 Sep;8(17):1044. doi:

10.21037/atm-20-3709. PMID: 33145263; PMCID: PMC7575984.

 

8: Mazzoni F, Petreni P, Vasile E, Panebianco M, Casadei-Gardini A, Negri F,

Lunghi A, Pillozzi S, Vivaldi C, Gervasi E, Frassineti GL, Messerini L, Jocollé

G, Bisagni A, Antonuzzo L, Rossi G. <i>ROS1</i> rearrangements are uncommon in

biliary tract cancers. Oncol Lett. 2020 Dec;20(6):316. doi:

10.3892/ol.2020.12179. Epub 2020 Oct 1. PMID: 33133252; PMCID: PMC7590438.

 

9: Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F,

Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi

S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F,

Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Correction

to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated

Hepatocellular Carcinoma. Target Oncol. 2020 Dec;15(6):809-810. doi:

10.1007/s11523-020-00765-3. Erratum for: Target Oncol. 2020 Dec;15(6):773-785.

PMID: 33113041.

 

10: Casadei Gardini A, Scarpi E, Valgiusti M, Monti M, Ruscelli S, Matteucci L,

Bartolini G, Vertogen B, Pagan F, Rovesti G, Frassineti GL, Passardi A.

Prognostic role of a new index (multi inflammatory index) in patients with

metastatic colorectal cancer: results from the randomized ITACa trial. Ther Adv

Med Oncol. 2020 Sep 28;12:1758835920958363. doi: 10.1177/1758835920958363. PMID:

33062063; PMCID: PMC7534088.

 

11: Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F,

Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi

S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F,

Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Prognostic

Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular

Carcinoma. Target Oncol. 2020 Dec;15(6):773-785. doi:

10.1007/s11523-020-00757-3. Erratum in: Target Oncol. 2020 Oct 28;: PMID:

33044683.

 

12: Canale M, Casadei-Gardini A, Ulivi P, Arechederra M, Berasain C, Lollini PL,

Fernández-Barrena MG, Avila MA. Epigenetic Mechanisms in Gastric Cancer:

Potential New Therapeutic Opportunities. Int J Mol Sci. 2020 Jul 31;21(15):5500.

doi: 10.3390/ijms21155500. PMID: 32752096; PMCID: PMC7432799.

 

13: Vivaldi C, Salani F, Rovesti G, Pecora I, Catanese S, Casadei-Gardini A,

Massa V, Bernardini L, Riggi L, Andrikou K, Rapposelli GI, Formica V, Lencioni

M, Falcone A, Vasile E, Fornaro L. First-line gemcitabine plus nab-paclitaxel

for elderly patients with metastatic pancreatic cancer: Crossing the frontier of

age? Eur J Cancer. 2020 Sep;137:108-116. doi: 10.1016/j.ejca.2020.06.031. Epub

2020 Aug 1. PMID: 32750500.

 

14: Roviello G, Casadei-Gardini A, Nobili S, Mini E, Fancelli S. Defining the

Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. J Oncol.

2020 Jun 19;2020:8024124. doi: 10.1155/2020/8024124. PMID: 32655640; PMCID:

PMC7321521.

 

15: Gelsomino F, Spallanzani A, Casadei-Gardini A. Comment on Chun et al, "A

Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus

Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable

Hepatic Colorectal Metastases". Clin Colorectal Cancer. 2020

Dec;19(4):e262-e263. doi: 10.1016/j.clcc.2020.06.002. Epub 2020 Jun 10. PMID:

32646655.

 

16: Vega-Benedetti AF, Loi E, Moi L, Orrù S, Ziranu P, Pretta A, Lai E, Puzzoni

M, Ciccone L, Casadei-Gardini A, Cabras F, Fortunato F, Restivo A, Zorcolo L,

Scartozzi M, Zavattari P. Colorectal Cancer Early Detection in Stool Samples

Tracing CpG Islands Methylation Alterations Affecting Gene Expression. Int J Mol

Sci. 2020 Jun 24;21(12):4494. doi: 10.3390/ijms21124494. PMID: 32599859; PMCID:

PMC7349989.

 

17: Neuzillet C, Casadei-Gardini A, Brieau B, Vivaldi C, Brandi G, Tougeron D,

Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi

M, Dahan L, Aprile G, Le Sourd S, Evesque L, Meurisse A, Lièvre A, Vernerey D;

AGEO (Association des Gastro-Entérologues Oncologues) Investigators; GICO

(Italian Group of Cholangiocarcinoma) Investigators. Fluropyrimidine single

agent or doublet chemotherapy as second line treatment in advanced biliary tract

cancer. Int J Cancer. 2020 Dec 1;147(11):3177-3188. doi: 10.1002/ijc.33146. Epub

2020 Jul 7. PMID: 32525595.

 

18: Casadei-Gardini A, Dadduzio V, Rovesti G, Cabibbo G, Vukotic R, Rizzato MD,

Orsi G, Rossi M, Guarneri V, Lonardi S, D'agostino D, Celsa C, Andreone P,

Zagonel V, Scartozzi M, Cascinu S, Cucchetti A. Utility of neutrophil-to-

lymphocyte ratio to identify long-term survivors among HCC patients treated with

sorafenib. Medicine (Baltimore). 2020 May 29;99(22):e19958. doi:

10.1097/MD.0000000000019958. PMID: 32481366.

 

19: Marconato L, Sabattini S, Marisi G, Rossi F, Leone VF, Casadei-Gardini A.

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma:

Preliminary Toxicity and Activity Data in Dogs. Cancers (Basel). 2020 May

18;12(5):1272. doi: 10.3390/cancers12051272. PMID: 32443457; PMCID: PMC7281367.

 

20: Gelsomino F, Casadei-Gardini A, Caputo F, Rossi G, Bertolini F, Petrachi T,

Spallanzani A, Pettorelli E, Kaleci S, Luppi G. mTOR Pathway Expression as

Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors

Treated with Everolimus. Cancers (Basel). 2020 May 10;12(5):1201. doi:

10.3390/cancers12051201. PMID: 32397669; PMCID: PMC7281483.

 

21: D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib

as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin

Pharmacol. 2020 Jun;13(6):623-629. doi: 10.1080/17512433.2020.1767591. Epub 2020

May 22. PMID: 32394749.

 

22: Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C,

Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F,

Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G,

Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to

predict survival in advanced hepatocellular carcinoma treated with Sorafenib.

PLoS One. 2020 May 7;15(5):e0232449. doi: 10.1371/journal.pone.0232449. PMID:

32379785; PMCID: PMC7205300.

 

23: Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P,

Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F,

Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari

F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Association of

<i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with

Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter

Prospective INNOVATE Study. Clin Cancer Res. 2020 Sep 1;26(17):4485-4493. doi:

10.1158/1078-0432.CCR-19-3897. Epub 2020 May 5. PMID: 32371540.

 

24: Gelsomino F, Casadei-Gardini A, Rossini D, Boccaccino A, Masi G, Cremolini

C, Spallanzani A, Viola MG, Garajovà I, Salati M, Elia MT, Caputo F, Santini C,

Falcone A, Cascinu S, Tamburini E. The Role of Anti-Angiogenics in Pre-Treated

Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis. Cancers

(Basel). 2020 Apr 21;12(4):1022. doi: 10.3390/cancers12041022. PMID: 32326305;

PMCID: PMC7226019.

 

25: Rimini M, Casadei-Gardini A, Ravaioli A, Rovesti G, Conti F, Borghi A,

Dall'Aglio AC, Bedogni G, Domenicali M, Giacomoni P, Tiribelli C, Bucchi L,

Falcini F, Foschi FG, Bagnacavallo Study Group. Could Inflammatory Indices and

Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the

Bagnacavallo Population Study. J Clin Med. 2020 Apr 20;9(4):1177. doi:

10.3390/jcm9041177. PMID: 32325965; PMCID: PMC7231063.

 

26: Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi

G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Is There an

Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. Clin

Colorectal Cancer. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001.

Epub 2020 Mar 17. PMID: 32192883.

 

27: de la Torre-Aláez M, Jordán-Iborra C, Casadei-Gardini A, Bilbao JI,

Rodriguez-Fraile M, Sancho L, D'Avola D, Herrero JI, Iñarrairaegui M, Sangro B.

The Pattern of Progression Defines Post-progression Survival in Patients with

Hepatocellular Carcinoma Treated with SIRT. Cardiovasc Intervent Radiol. 2020

Aug;43(8):1165-1172. doi: 10.1007/s00270-020-02444-2. Epub 2020 Mar 12. PMID:

32166352.

 

28: Cucchetti A, Evans D, Casadei-Gardini A, Piscaglia F, Maroni L, Odaldi F,

Ercolani G. The Perceived Ability of Gastroenterologists, Hepatologists and

Surgeons Can Bias Medical Decision Making. Int J Environ Res Public Health. 2020

Feb 7;17(3):1058. doi: 10.3390/ijerph17031058. PMID: 32046089; PMCID:

PMC7037552.

 

29: Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi G,

Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E,

Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M.

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced

Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Target Oncol.

2020 Feb;15(1):115-126. doi: 10.1007/s11523-020-00698-x. Erratum in: Target

Oncol. 2020 Dec;15(6):801-802. PMID: 32020517.

 

30: Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M,

Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri

F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F.

MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i>/<i>TP53</i> Axis and

Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Res. 2020 Apr

15;80(8):1720-1734. doi: 10.1158/0008-5472.CAN-19-0472. Epub 2020 Feb 3. PMID:

32015093.

 

31: Casadei-Gardini A, Del Coco L, Marisi G, Conti F, Rovesti G, Ulivi P, Canale

M, Frassineti GL, Foschi FG, Longo S, Fanizzi FP, Giudetti AM. ¹H-NMR

Based Serum Metabolomics Highlights Different Specific Biomarkers between Early

and Advanced Hepatocellular Carcinoma Stages. Cancers (Basel). 2020 Jan

18;12(1):241. doi: 10.3390/cancers12010241. PMID: 31963766; PMCID: PMC7016798.

 

32: Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A,

Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL,

Romeo A. Erratum: Passardi, A. et al<i>.</i> Chemoradiotherapy (Gemox Plus

Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A

Phase II Study. <i>Cancers</i> 2019, <i>11</i>, 663. Cancers (Basel). 2020 Jan

10;12(1):178. doi: 10.3390/cancers12010178. Erratum for: Cancers (Basel). 2019

May 13;11(5): PMID: 31936817; PMCID: PMC7016811.

 

33: Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive

biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther.

2020 Jan;20(1):63-74. doi: 10.1080/14737140.2020.1712198. Epub 2020 Jan 7. PMID:

31910040.

 

34: Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K,

Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P,

Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N,

Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. The prognostic

nutritional index predicts survival and response to first-line chemotherapy in

advanced biliary cancer. Liver Int. 2020 Mar;40(3):704-711. doi:

10.1111/liv.14314. Epub 2019 Dec 11. PMID: 31773848.

 

35: Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG,

Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M,

Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P,

Scartozzi M, Cascinu S, Casadei-Gardini A. Impact of Baseline Characteristics on

the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of

Experience. Gastrointest Tumors. 2019 Oct;6(3-4):92-107. doi: 10.1159/000502714.

Epub 2019 Sep 12. PMID: 31768353; PMCID: PMC6873043.

 

36: Casadei-Gardini A, Solaini L, Riggi L, Molinaro E, Dadduzio V, Rizzato MD,

Pellino A, Faloppi L, Marisi G, Ulivi P, Canale M, Orsi G, Rovesti G, Andrikou

K, Spallanzani A, Gelsomino F, Foschi FG, Conti F, Cucchetti A, Ercolani G,

Biason P, Lonardi S, Cascinu S, Scartozzi M. Prognostic Role of a New Index

(RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib:

Training and Validation Cohort. Gastrointest Tumors. 2019 Oct;6(3-4):71-80. doi:

10.1159/000501593. Epub 2019 Aug 20. PMID: 31768351; PMCID: PMC6873000.

 

37: Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A,

Andrikou K, Cascinu S, Gelsomino F. BRAF-Mutated Colorectal Cancer: Clinical and

Molecular Insights. Int J Mol Sci. 2019 Oct 28;20(21):5369. doi:

10.3390/ijms20215369. PMID: 31661924; PMCID: PMC6861966.

 

38: Brunetti O, Gnoni A, Licchetta A, Longo V, Calabrese A, Argentiero A,

Delcuratolo S, Solimando AG, Casadei-Gardini A, Silvestris N. Predictive and

Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Kaunas).

2019 Oct 21;55(10):707. doi: 10.3390/medicina55100707. PMID: 31640191; PMCID:

PMC6843290.

 

39: Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro

F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per

lo Studio del Fegato (AISF) HCC Special Interest Group. Platelets and

Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers (Basel). 2019

Oct 15;11(10):1568. doi: 10.3390/cancers11101568. PMID: 31618961; PMCID:

PMC6826649.

 

40: Cabibbo G, Cucchetti A, Cammà C, Casadei-Gardini A, Celsa C, Emanuele Maria

Rizzo G, Johnson P, Ercolani G. Outcomes of hepatocellular carcinoma patients

treated with sorafenib: a meta-analysis of Phase III trials. Future Oncol. 2019

Oct;15(29):3411-3422. doi: 10.2217/fon-2019-0287. Epub 2019 Oct 7. PMID:

31588789.

 

41: Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A,

Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J,

Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P,

Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F. Validated Nomogram

Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line

5-Fluorouracil, Oxaliplatin, and Irinotecan. Clin Colorectal Cancer. 2019

Dec;18(4):e394-e401. doi: 10.1016/j.clcc.2019.08.004. Epub 2019 Sep 4. PMID:

31564556.

 

42: Orsi G, Casadei-Gardini A. Sorafenib and metformin: to be, or not to be,

that is the question. Hepatobiliary Surg Nutr. 2019 Aug;8(4):411-413. doi:

10.21037/hbsn.2019.04.01. PMID: 31489317; PMCID: PMC6700026.

 

43: Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G,

Negrini G, Orsi G, Renzulli M, Piscaglia F. Management of adverse events with

tailored sorafenib dosing prolongs survival of hepatocellular carcinoma

patients. J Hepatol. 2019 Dec;71(6):1175-1183. doi: 10.1016/j.jhep.2019.08.015.

Epub 2019 Aug 23. PMID: 31449860.

 

44: Casadei-Gardini A, Montagnani F, Casadei C. Immune inflammation indicators

in anal cancer patients treated with concurrent chemoradiation: training and

validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

[Corrigendum]. Cancer Manag Res. 2019 Jun 25;11:5123. doi: 10.2147/CMAR.S215110.

Erratum for: Cancer Manag Res. 2019 Apr 26;11:3631-3642. PMID: 31417303; PMCID:

PMC6599855.

 

45: Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone

M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti

F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini

A. <i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced

Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers (Basel). 2019 Jul

20;11(7):1023. doi: 10.3390/cancers11071023. PMID: 31330833; PMCID: PMC6679015.

 

46: Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, Arcella A,

Badiali M, Giangaspero F, Morra I, Columbano A, Restivo A, Zorcolo L, Gismondi

V, Varesco L, Bellomo SE, Giordano S, Canale M, Casadei-Gardini A, Faloppi L,

Puzzoni M, Scartozzi M, Ziranu P, Cabras G, Cocco P, Ennas MG, Satta G, Zucca M,

Canzio D, Zavattari P. Clustered protocadherins methylation alterations in

cancer. Clin Epigenetics. 2019 Jul 9;11(1):100. doi: 10.1186/s13148-019-0695-0.

PMID: 31288858; PMCID: PMC6617643.

 

47: Vergara D, Casadei-Gardini A, Giudetti AM. Oxidative Molecular Mechanisms

Underlying Liver Diseases: From Systems Biology to the Personalized Medicine.

Oxid Med Cell Longev. 2019 Jun 2;2019:7864316. doi: 10.1155/2019/7864316. PMID:

31281591; PMCID: PMC6589262.

 

48: Tovoli F, Casadei-Gardini A, Benevento F, Piscaglia F. Immunotherapy for

hepatocellular carcinoma: A review of potential new drugs based on ongoing

clinical studies as of 2019. Dig Liver Dis. 2019 Aug;51(8):1067-1073. doi:

10.1016/j.dld.2019.05.006. Epub 2019 Jun 14. PMID: 31208929.

 

49: Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini

I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M,

Frassineti GL, Passardi A. Prognostic role of a new inflammatory index with

neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon

Inflammatory Index) in patients with metastatic colorectal cancer: results from

the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. Cancer

Manag Res. 2019 May 10;11:4357-4369. doi: 10.2147/CMAR.S198651. Erratum in:

Cancer Manag Res. 2020 Jan 23;12:541. PMID: 31191000; PMCID: PMC6522652.

 

50: Solaini L, Gardini A, Passardi A, Mirarchi MT, D'Acapito F, La Barba G,

Cucchi M, Casadei Gardini A, Frassineti GL, Cucchetti A, Ercolani G.

Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver

Metastasis Patients: A Propensity Score-Matched Analysis. Am Surg. 2019 May

1;85(5):488-493. PMID: 31126361.

 

51: Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi

D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC,

Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V,

Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P.

Immune inflammation indicators in anal cancer patients treated with concurrent

chemoradiation: training and validation cohort with online calculator (ARC: Anal

Cancer Response Classifier). Cancer Manag Res. 2019 Apr 26;11:3631-3642. doi:

10.2147/CMAR.S197349. Erratum in: Cancer Manag Res. 2019 Jun 25;11:5123. PMID:

31118786; PMCID: PMC6506779.

 

52: Casadei Gardini A, Puzzoni M, Montagnani F, Marisi G, Tamburini E, Cucchetti

A, Solaini L, Foschi FG, Conti F, Ercolani G, Cascinu S, Scartozzi M. Profile of

lenvatinib in the treatment of hepatocellular carcinoma: design, development,

potential place in therapy and network meta-analysis of hepatitis B and

hepatitis C in all Phase III trials. Onco Targets Ther. 2019 Apr

24;12:2981-2988. doi: 10.2147/OTT.S192572. PMID: 31118665; PMCID: PMC6499482.

 

53: Del Coco L, Vergara D, De Matteis S, Mensà E, Sabbatinelli J, Prattichizzo

F, Bonfigli AR, Storci G, Bravaccini S, Pirini F, Ragusa A, Casadei-Gardini A,

Bonafè M, Maffia M, Fanizzi FP, Olivieri F, Giudetti AM. NMR-Based Metabolomic

Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients

with Type 2 Diabetes Mellitus. J Clin Med. 2019 May 21;8(5):720. doi:

10.3390/jcm8050720. PMID: 31117294; PMCID: PMC6571571.

 

54: Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, La

Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL,

Romeo A. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable

Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers (Basel). 2019 May

13;11(5):663. doi: 10.3390/cancers11050663. Erratum in: Cancers (Basel). 2020

Jan 10;12(1): PMID: 31086093; PMCID: PMC6562444.

 

55: Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G,

Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De

Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D,

Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi

G, Scarpa A, Cascinu S, Silvestris N. The Italian Rare Pancreatic Exocrine

Cancer Initiative. Tumori. 2019 Aug;105(4):353-358. doi:

10.1177/0300891619839461. Epub 2019 Apr 9. Erratum in: Tumori. 2020 Mar

16;:300891620914460. PMID: 30967031.

 

56: Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y,

Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath

I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS,

Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators. Doxorubicin-

loaded nanoparticles for patients with advanced hepatocellular carcinoma after

sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi:

10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Erratum in: Lancet Gastroenterol

Hepatol. 2019 Jul;4(7):e6. Erratum in: Lancet Gastroenterol Hepatol. 2020

Feb;5(2):e1. PMID: 30954567.

 

57: Solaini L, D'Acapito F, Passardi A, Framarini M, Tauceri F, Di Pietrantonio

D, Frassineti GL, Casadei Gardini A, Cucchetti A, Cavaliere D, Ercolani G.

Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal

carcinomatosis in colorectal cancer patients: a single-center cohort study.

World J Surg Oncol. 2019 Mar 27;17(1):58. doi: 10.1186/s12957-019-1602-z. PMID:

30917826; PMCID: PMC6437853.

 

58: De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G,

Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A,

Ercolani G, Santini D, Frassineti GL, Faloppi L, Scartozzi M, Cascinu S,

Casadei-Gardini A. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma

Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with

Metformin. Int J Mol Sci. 2019 Mar 26;20(6):1503. doi: 10.3390/ijms20061503.

PMID: 30917505; PMCID: PMC6470641.

 

59: Cucchetti A, Casadei Gardini A. Incorporating alpha-fetoprotein within

dimensional criteria for hepatocellular carcinoma transplantation. Hepatobiliary

Surg Nutr. 2019 Feb;8(1):65-66. doi: 10.21037/hbsn.2018.11.02. PMID: 30881969;

PMCID: PMC6383020.

 

60: Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G,

Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau

B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S,

Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues

Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave

Roussy Institute Cohort; Barts Cancer Institute Cohort. Prediction of survival

with second-line therapy in biliary tract cancer: Actualisation of the AGEO

CT2BIL cohort and European multicentre validations. Eur J Cancer. 2019

Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1. PMID:

30826661.

 

61: De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafè

M, Giudetti AM. Aberrant Metabolism in Hepatocellular Carcinoma Provides

Diagnostic and Therapeutic Opportunities. Oxid Med Cell Longev. 2018 Nov

4;2018:7512159. doi: 10.1155/2018/7512159. PMID: 30524660; PMCID: PMC6247426.

 

62: Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei

Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P. IL-8 and thrombospondin-1

as prognostic markers in patients with metastatic colorectal cancer receiving

bevacizumab. Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi:

10.2147/CMAR.S181570. PMID: 30532588; PMCID: PMC6241685.

 

63: Casadei Gardini A, Scarpi E, Foschi FG, Marisi G, Maltoni M, Frassineti GL.

Impact of physician experience and multidisciplinary team on clinical outcome in

patients receiving sorafenib. Clin Res Hepatol Gastroenterol. 2019

Oct;43(5):e76-e78. doi: 10.1016/j.clinre.2018.11.005. Epub 2018 Dec 5. PMID:

30528062.

 

64: Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B.

Radioembolization versus chemoembolization for unresectable hepatocellular

carcinoma: a meta-analysis of randomized trials. Onco Targets Ther. 2018 Oct

25;11:7315-7321. doi: 10.2147/OTT.S175715. PMID: 30498358; PMCID: PMC6207245.

 

65: Foschi FG, Bedogni G, Domenicali M, Giacomoni P, Dall'Aglio AC, Dazzani F,

Lanzi A, Conti F, Savini S, Saini G, Bernardi M, Andreone P, Gastaldelli A,

Casadei Gardini A, Tiribelli C, Bellentani S, Stefanini GF. Prevalence of and

risk factors for fatty liver in the general population of Northern Italy: the

Bagnacavallo Study. BMC Gastroenterol. 2018 Nov 28;18(1):177. doi:

10.1186/s12876-018-0906-8. PMID: 30486798; PMCID: PMC6262973.

 

66: Scarpi E, Dall'Agata M, Zagonel V, Gamucci T, Bertè R, Sansoni E, Amaducci

E, Broglia CM, Alquati S, Garetto F, Schiavon S, Quadrini S, Orlandi E, Casadei

Gardini A, Ruscelli S, Ferrari D, Pino MS, Bortolussi R, Negri F, Stragliotto S,

Narducci F, Valgiusti M, Farolfi A, Nanni O, Rossi R, Maltoni M; Early

Palliative Care Italian Study Group (EPCISG). Systematic vs. on-demand early

palliative care in gastric cancer patients: a randomized clinical trial

assessing patient and healthcare service outcomes. Support Care Cancer. 2019

Jul;27(7):2425-2434. doi: 10.1007/s00520-018-4517-2. Epub 2018 Oct 24. PMID:

30357555.

 

67: Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G,

Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L,

Mazzella G, Brillanti S, Andreone P; member of the Bologna DAA group. Immune

inflammation indicators and ALBI score to predict liver cancer in HCV-patients

treated with direct-acting antivirals. Dig Liver Dis. 2019 May;51(5):681-688.

doi: 10.1016/j.dld.2018.09.016. Epub 2018 Sep 22. PMID: 30327251.

 

68: Casadei Gardini A, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G,

Valgiusti M, Passardi A, Frassineti GL, Scarpi E. Radiofrequency ablation of

hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-

free survival. Onco Targets Ther. 2018 Oct 5;11:6555-6567. doi:

10.2147/OTT.S170836. PMID: 30323628; PMCID: PMC6178942.

 

69: Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG,

De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei

Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any

predictive and/or prognostic markers? World J Gastroenterol. 2018 Sep

28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152. PMID: 30271080; PMCID:

PMC6158485.

 

70: Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I,

Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL,

Amadori D, Passardi A. Prognostic role of aspartate aminotransferase-lymphocyte

ratio index in patients with metastatic colorectal cancer: results from the

randomized ITACa trial. Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi:

10.2147/OTT.S166614. PMID: 30214231; PMCID: PMC6120511.

 

71: Franco P, De Bari B, Arcadipane F, Lepinoy A, Ceccarelli M, Furfaro G,

Mistrangelo M, Cassoni P, Valgiusti M, Passardi A, Casadei Gardini A, Trino E,

Martini S, Iorio GC, Evangelista A, Ricardi U, Créhange G. Comparing

simultaneous integrated boost vs sequential boost in anal cancer patients:

results of a retrospective observational study. Radiat Oncol. 2018 Sep

10;13(1):172. doi: 10.1186/s13014-018-1124-9. PMID: 30201015; PMCID: PMC6131808.

 

72: Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F; Special

Interest Group on Hepatocellular carcinoma and new anti-HCV therapies” of the

Italian Association for the Study of the Liver. Recurrence of hepatocellular

carcinoma after direct acting antiviral treatment for hepatitis C virus

infection: Literature review and risk analysis. Dig Liver Dis. 2018

Nov;50(11):1105-1114. doi: 10.1016/j.dld.2018.08.001. Epub 2018 Aug 11. PMID:

30170908.

 

73: Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G,

Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G,

Frassineti GL, Casadei Gardini A. Clinical and circulating biomarkers of

survival and recurrence after radiofrequency ablation in patients with

hepatocellular carcinoma. Crit Rev Oncol Hematol. 2018 Sep;129:44-53. doi:

10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. PMID: 30097237.

 

74: Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Passardi A,

Casadei Gardini A, Frassineti GL, Gaiarsa S, Albertini AM, Ranzani GN, Calistri

D, Pasca MR. Shifts of Faecal Microbiota During Sporadic Colorectal

Carcinogenesis. Sci Rep. 2018 Jul 9;8(1):10329. doi: 10.1038/s41598-018-28671-9.

PMID: 29985435; PMCID: PMC6037773.

 

75: Massa I, Nanni O, Foca F, Maltoni M, Derni S, Gentili N, Frassineti GL,

Casadei Gardini A, Valgiusti M, Amadori D, Prati E, Altini M, Gallegati D,

Sansoni E. Chemotherapy and palliative care near end-of life: examining the

appropriateness at a cancer institute for colorectal cancer patients. BMC

Palliat Care. 2018 Jun 19;17(1):86. doi: 10.1186/s12904-018-0339-8. PMID:

29914452; PMCID: PMC6006864.

 

76: Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M,

Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R,

Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D,

Reni M, Cascinu S, Silvestris N. Systemic Chemotherapy for Advanced Rare

Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. Pancreas.

2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063. PMID: 29771769.

 

77: Casadei Gardini A, Conti F, Foschi FG, Brillanti S, Andreone P; members of

Bologna DAA group. Imbalance of Neutrophils and Lymphocyte Counts Can Be

Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related

Cirrhosis Treated With Direct-acting Antivirals. Gastroenterology. 2018

Jun;154(8):2281-2282. doi: 10.1053/j.gastro.2017.12.051. Epub 2018 May 7. PMID:

29746809.

 

78: Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG,

Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F,

Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G,

Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F;

Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across

hepatocellular carcinoma in Italy. Liver Int. 2018 Nov;38(11):2028-2039. doi:

10.1111/liv.13877. Epub 2018 Jun 19. PMID: 29745475.

 

79: Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Martini S,

Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Cascinu S, Ricardi

U, Casadei Gardini A. The prognostic role of hemoglobin levels in patients

undergoing concurrent chemo-radiation for anal cancer. Radiat Oncol. 2018 May

2;13(1):83. doi: 10.1186/s13014-018-1035-9. PMID: 29720197; PMCID: PMC5930791.

 

80: Casadei Gardini A, Passardi A, Fornaro L, Rosetti P, Valgiusti M, Ruscelli

S, Monti M, Casadei C, Pagan F, Frassineti GL. Treatment of squamous cell

carcinoma of the anal canal: A new strategies with anti-EGFR therapy and

immunotherapy. Crit Rev Oncol Hematol. 2018 Mar;123:52-56. doi:

10.1016/j.critrevonc.2018.01.007. Epub 2018 Feb 2. PMID: 29482779.

 

81: Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, Rossi A,

Ferroni F, Ragazzini A, Casadei Gardini A, Frassineti GL, Gavelli G, Passardi A.

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of

bevacizumab efficacy in patients with metastatic colorectal cancer. Eur Radiol.

2018 Jul;28(7):2969-2978. doi: 10.1007/s00330-017-5254-5. Epub 2018 Feb 7. PMID:

29417252.

 

82: Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A,

Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F,

Sacco R, Di Costanzo GG. Metronomic capecitabine as second-line treatment for

hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin

Oncol. 2018 Feb;144(2):403-414. doi: 10.1007/s00432-017-2556-6. Epub 2017 Dec

16. PMID: 29249005.

 

83: Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG,

Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti

O, Cardellino GG, Frassineti GL, Scartozzi M. Antiangiogenic agents after first

line and sorafenib plus chemoembolization: a systematic review. Oncotarget. 2017

Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. PMID: 29029548; PMCID:

PMC5630448.

 

84: Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli

F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G,

Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi

A, Santini D, Cascinu S, Frassineti GL, Scartozzi M. Metformin and insulin

impact on clinical outcome in patients with advanced hepatocellular carcinoma

receiving sorafenib: Validation study and biological rationale. Eur J Cancer.

2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3. PMID:

28985579.

 

85: Casadei Gardini A, Valgiusti M, Passardi A, Frassineti GL. Treatment of

squamous cell carcinoma of the anal canal (SCCA): a new era? Ann Oncol. 2017 Oct

1;28(10):2620. doi: 10.1093/annonc/mdx291. PMID: 28945890.

 

86: Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D,

Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M,

Ulivi P, Amadori D. Impact of second-line cetuximab-containing therapy in

patients with KRAS wild-type metastatic colorectal cancer: results from the

ITACa randomized clinical trial. Sci Rep. 2017 Sep 5;7(1):10426. doi:

10.1038/s41598-017-11048-9. PMID: 28874797; PMCID: PMC5585399.

 

87: Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata

R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G,

Tortora R. Validation of a Simple Scoring System to Predict Sorafenib

Effectiveness in Patients with Hepatocellular Carcinoma. Target Oncol. 2017

Dec;12(6):795-803. doi: 10.1007/s11523-017-0522-5. PMID: 28770532.

 

88: Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei

Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi

A. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor

Biology and Bevacizumab Efficacy. Int J Mol Sci. 2017 Jun 9;18(6):1240. doi:

10.3390/ijms18061240. PMID: 28598398; PMCID: PMC5486063.

 

89: Passardi A, Fanini F, Turci L, Foca F, Rosetti P, Ruscelli S, Casadei

Gardini A, Valgiusti M, Dazzi C, Marangolo M. Prolonged Pemetrexed Infusion Plus

Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale

and Phase II Study Results. Oncologist. 2017 Aug;22(8):886-e79. doi:

10.1634/theoncologist.2017-0206. Epub 2017 Jun 7. PMID: 28592624; PMCID:

PMC5553965.

 

90: Casadei Gardini A, Frassineti GL, Foschi FG, Ercolani G, Ulivi P. Sorafenib

and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients:

Analysis of RESORCE and SHARP trials. Dig Liver Dis. 2017 Aug;49(8):943-944.

doi: 10.1016/j.dld.2017.04.022. Epub 2017 May 6. PMID: 28546063.

 

91: De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D,

Foschi FG, Ercolani G, Vespasiani Gentilucci U, Faloppi L, Scartozzi M,

Frassineti GL, Casadei Gardini A. Interplay Between SIRT-3, Metabolism and Its

Tumor Suppressor Role in Hepatocellular Carcinoma. Dig Dis Sci. 2017

Aug;62(8):1872-1880. doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19. PMID:

28527050.

 

92: Ongaro E, Buoro V, Cinausero M, Caccialanza R, Turri A, Fanotto V, Basile D,

Vitale MG, Ermacora P, Cardellino GG, Nicoletti L, Fornaro L, Casadei-Gardini A,

Aprile G. Sarcopenia in gastric cancer: when the loss costs too much. Gastric

Cancer. 2017 Jul;20(4):563-572. doi: 10.1007/s10120-017-0722-9. Epub 2017 May 5.

PMID: 28477106.

 

93: Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei

Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P. Circulating VEGF and eNOS

variations as predictors of outcome in metastatic colorectal cancer patients

receiving bevacizumab. Sci Rep. 2017 May 2;7(1):1293. doi:

10.1038/s41598-017-01420-0. PMID: 28465540; PMCID: PMC5431064.

 

94: Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M,

Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O.

Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget. 2017 May

16;8(20):33897-33910. doi: 10.18632/oncotarget.15406. PMID: 28420805; PMCID:

PMC5464921.

 

95: Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M,

Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M,

Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M,

Calvetti L, Cardarelli N, Aprile G. Immunotherapy for colorectal cancer: where

are we heading? Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi:

10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Erratum in: Expert Opin Biol

Ther. 2017 Jun;17 (6):791. PMID: 28375039.

 

96: Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V,

Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG,

Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S.

Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev

Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub

2017 Feb 4. PMID: 28259290.

 

97: Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi

L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani

G, Tassinari D, Cascinu S, Frassineti GL. Metronomic capecitabine versus best

supportive care as second-line treatment in hepatocellular carcinoma: a

retrospective study. Sci Rep. 2017 Feb 13;7:42499. doi: 10.1038/srep42499. PMID:

28211921; PMCID: PMC5304169.

 

98: Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Casadei Gardini

A, Marisi G, Baron Toaldo M, Baglioni M, Salvatore V, Callegari E, Baldassarre

M, Galassi M, Giovannini C, Cescon M, Ravaioli M, Negrini M, Bolondi L,

Gramantieri L. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib

Resistance through Inhibition of Caspase-3-Mediated Apoptosis. Clin Cancer Res.

2017 Jul 15;23(14):3953-3965. doi: 10.1158/1078-0432.CCR-16-1464. Epub 2017 Jan

17. PMID: 28096271.

 

99: Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codecà C, Broglia

CM, Sansoni E, Bortolussi R, Garetto F, Fioretto L, Cattaneo MT, Giacobino A,

Luzzani M, Luchena G, Alquati S, Quadrini S, Zagonel V, Cavanna L, Ferrari D,

Pedrazzoli P, Frassineti GL, Galiano A, Casadei Gardini A, Monti M, Nanni O;

Early Palliative Care Italian Study Group (EPCISG). Erratum to "Systematic

versus on-demand early palliative care: A randomised clinical trial assessing

quality of care and treatment aggressiveness near the end of life" [Eur J Cancer

69 (2016) 110-118]. Eur J Cancer. 2017 Feb;72:272-273. doi:

10.1016/j.ejca.2016.11.024. Epub 2016 Dec 24. Erratum for: Eur J Cancer. 2016

Dec;69:110-118. PMID: 28027830.

 

100: Capelli L, Casadei Gardini A, Scarpi E, Frassineti GL, Saragoni L, Puccetti

M, Scartozzi M, Giannini M, Tamberi S, Corbelli J, Ulivi P. No evidence of NRAS

mutation in squamous cell anal carcinoma (SCAC). Sci Rep. 2016 Nov 25;6:37621.

doi: 10.1038/srep37621. PMID: 27886225; PMCID: PMC5122846.

 

101: Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codecà C, Broglia

CM, Sansoni E, Bortolussi R, Garetto F, Fioretto L, Cattaneo MT, Giacobino A,

Luzzani M, Luchena G, Alquati S, Quadrini S, Zagonel V, Cavanna L, Ferrari D,

Pedrazzoli P, Frassineti GL, Galiano A, Casadei Gardini A, Monti M, Nanni O;

Early Palliative Care Italian Study Group (EPCISG). Systematic versus on-demand

early palliative care: A randomised clinical trial assessing quality of care and

treatment aggressiveness near the end of life. Eur J Cancer. 2016

Dec;69:110-118. doi: 10.1016/j.ejca.2016.10.004. Epub 2016 Nov 4. Erratum in:

Eur J Cancer. 2017 Feb;72 :272-273. PMID: 27821313.

 

102: Casadei Gardini A, Tenti E, Masini C, Nanni O, Scarpi E, Valgiusti M,

Restuccia S, Gallani ML, Palazzini S, Bianchini E, Menozzi S, Maugeri A, Amadori

D, Minguzzi M, Frassineti GL. Multicentric survey on dose reduction/interruption

of cancer drug therapy in 12.472 patients: indicators of suspected adverse

reactions. Oncotarget. 2016 Jun 28;7(26):40719-40724. doi:

10.18632/oncotarget.8942. PMID: 27119511; PMCID: PMC5130038.

 

103: Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini

D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G,

Frassineti GL. Immune inflammation indicators and implication for immune

modulation strategies in advanced hepatocellular carcinoma patients receiving

sorafenib. Oncotarget. 2016 Oct 11;7(41):67142-67149. doi:

10.18632/oncotarget.11565. PMID: 27613839; PMCID: PMC5341863.

 

104: Maltoni M, Scarpi E, Dall'Agata M, Zagonel V, Bertè R, Ferrari D, Broglia

CM, Bortolussi R, Trentin L, Valgiusti M, Pini S, Farolfi A, Casadei Gardini A,

Nanni O, Amadori D; Early Palliative Care Italian Study Group (EPCISG).

Systematic versus on-demand early palliative care: results from a multicentre,

randomised clinical trial. Eur J Cancer. 2016 Sep;65:61-8. doi:

10.1016/j.ejca.2016.06.007. Epub 2016 Jul 26. PMID: 27472648.

 

105: Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi

M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P. Efficacy

of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response

in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC

Cancer. 2016 Jul 7;16:429. doi: 10.1186/s12885-016-2463-2. PMID: 27388325;

PMCID: PMC4937544.

 

106: Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A,

Andrikou K, Del Prete M, Cascinu S, Scartozzi M. Lactate Dehydrogenase in

Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int.

2016;2016:7196280. doi: 10.1155/2016/7196280. Epub 2016 May 29. PMID: 27314036;

PMCID: PMC4903134.

 

107: Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N,

Bianconi M, Giampieri R, Valgiusti M, Brunetti O, Bittoni A, Andrikou K, Lai E,

Dessì A, Cascinu S, Scartozzi M. The correlation between LDH serum levels and

clinical outcome in advanced biliary tract cancer patients treated with first

line chemotherapy. Sci Rep. 2016 Apr 11;6:24136. doi: 10.1038/srep24136. PMID:

27063994; PMCID: PMC4827080.

 

108: Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M,

Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM,

Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P,

Frassineti GL. eNOS polymorphisms and clinical outcome in advanced HCC patients

receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016 May

10;7(19):27988-99. doi: 10.18632/oncotarget.8569. PMID: 27058899; PMCID:

PMC5053704.

 

109: Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E,

Faloppi L, Scartozzi M, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba

G, Veneroni L, Tamberi S, Cascinu S, Frassineti GL. Early onset of hypertension

and serum electrolyte changes as potential predictive factors of activity in

advanced HCC patients treated with sorafenib: results from a retrospective

analysis of the HCC-AVR group. Oncotarget. 2016 Mar 22;7(12):15243-51. doi:

10.18632/oncotarget.7444. PMID: 26893366; PMCID: PMC4924783.

 

110: Casadei Gardini A, Mariotti M, Lucchesi A, Pini S, Valgiusti M, Bravaccini

S, Del Monte A, Burgio MA, Marisi G, Amadori D, Frassineti GL. Paraneoplastic

lipase and amylase production in a patient with small-cell lung cancer: case

report. BMC Cancer. 2016 Feb 17;16:118. doi: 10.1186/s12885-016-2167-7. PMID:

26887807; PMCID: PMC4758001.

 

111: Casadei Gardini A, Carloni S, Scarpi E, Maltoni P, Dorizzi RM, Passardi A,

Frassineti GL, Cortesi P, Giannini MB, Marisi G, Amadori D, Lucchesi A.

Prognostic role of serum concentrations of high-sensitivity C-reactive protein

in patients with metastatic colorectal cancer: results from the ITACa trial.

Oncotarget. 2016 Mar 1;7(9):10193-202. doi: 10.18632/oncotarget.7166. PMID:

26848624; PMCID: PMC4891113.

 

112: Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris

N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E,

Ricca Rosellini S, Ulivi P, Cascinu S, Nanni O, Frassineti GL. Effects of

metformin on clinical outcome in diabetic patients with advanced HCC receiving

sorafenib. Expert Opin Pharmacother. 2015;16(18):2719-25. doi:

10.1517/14656566.2015.1102887. Epub 2015 Oct 29. PMID: 26513009.

 

113: Lucchesi A, Fattori PP, Ronconi S, Carloni S, Casadei Gardini A, Musuraca

G, Napolitano M. Atypical presentations of thrombotic thrombocytopenic purpura

in middle-aged women with recurrent cerebral macrovascular thrombosis: a case

report. Ann Hematol. 2015 Sep;94(9):1597-8. doi: 10.1007/s00277-015-2415-y. Epub

2015 Jun 9. PMID: 26051903.

 

114: Rengucci C, De Maio G, Menghi M, Scarpi E, Guglielmo S, Fusaroli P, Caletti

G, Saragoni L, Casadei Gardini A, Zoli W, Falcini F, Amadori D, Calistri D.

Improved stool DNA integrity method for early colorectal cancer diagnosis.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2553-60. doi:

10.1158/1055-9965.EPI-14-0379. Epub 2014 Aug 15. PMID: 25128402.

 

115: Rengucci C, De Maio G, Casadei Gardini A, Zucca M, Scarpi E, Zingaretti C,

Foschi G, Tumedei MM, Molinari C, Saragoni L, Puccetti M, Amadori D, Zoli W,

Calistri D. Promoter methylation of tumor suppressor genes in pre-neoplastic

lesions; potential marker of disease recurrence. J Exp Clin Cancer Res. 2014 Aug

5;33(1):65. doi: 10.1186/s13046-014-0065-x. PMID: 25091577; PMCID: PMC4274757.

 

116: Cecconetto L, Casadei Gardini A, Tenti E, Maltoni R, Bravaccini S, Oboldi

D, Zoli W, Serra P, Donati C, Sarti S, Amadori D, Rocca A. Long-term complete

response in a patient with liver metastases from breast cancer treated with

metronomic chemotherapy. Tumori. 2014 May-Jun;100(3):e79-82. doi:

10.1700/1578.17238. PMID: 25076256.

 

117: Casadei Gardini A, Capelli L, Ulivi P, Giannini M, Freier E, Tamberi S,

Scarpi E, Passardi A, Zoli W, Ragazzini A, Amadori D, Frassineti GL. KRAS, BRAF

and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS One. 2014 Mar

18;9(3):e92071. doi: 10.1371/journal.pone.0092071. PMID: 24642661; PMCID:

PMC3958420.

 

118: Terragni R, Casadei Gardini A, Sabattini S, Bettini G, Amadori D, Talamonti

C, Vignoli M, Capelli L, Saunders JH, Ricci M, Ulivi P. EGFR, HER-2 and KRAS in

canine gastric epithelial tumors: a potential human model? PLoS One. 2014 Jan

15;9(1):e85388. doi: 10.1371/journal.pone.0085388. Erratum in: PLoS One.

2015;10(3):e0119048. PMID: 24454858; PMCID: PMC3893207.

 

119: Monti M, Foca F, Casadei Gardini A, Valgiusti M, Frassineti GL, Amadori D.

Retrospective analysis on the management of metastatic gastric cancer patients.

A mono-institutional experience. What happens in clinical practice? Tumori. 2013

Sep-Oct;99(5):583-8. doi: 10.1700/1377.15306. PMID: 24362861.

 

120: Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E,

Burgio MA, Amadori D, Frassineti GL. Separate episodes of capillary leak

syndrome and pulmonary hypertension after adjuvant gemcitabine and three years

later after nab-paclitaxel for metastatic disease. BMC Cancer. 2013 Nov

12;13:542. doi: 10.1186/1471-2407-13-542. PMID: 24215543; PMCID: PMC3840643.

 

121: Burgio SL, Menna C, Papiani G, Casadei Gardini A, De Luigi N, Corsi R,

Rosti G. Alpha-fetoprotein surge following high-dose chemotherapy in germ cell

tumours. J Chemother. 2013 Apr;25(2):119-22. doi:

10.1179/1973947812Y.0000000044. PMID: 23684360.

 

122: Lucchesi A, Carloni S, Cangini D, Frassineti GL, Casadei Gardini A. Acute

oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report and

results from a cytoflourimetric assay of platelet fibrinogen receptor. J Clin

Oncol. 2013 Jun 1;31(16):2061-2. doi: 10.1200/JCO.2012.48.3248. Epub 2013 Apr

22. PMID: 23610122.

 

123: Casadei Gardini A, Pieri F, Fusaroli P, Oboldi D, Passardi A, Monti M,

Rosetti P, Calpona S, Valgiusti M, Ragazzini A, Amadori D, Frassineti GL.

Hemangioblastoma of the gastrointestinal tract: a first case. Int J Surg Pathol.

2013 Apr;21(2):192-6. doi: 10.1177/1066896912475082. PMID: 23516170.

 

124: Clavarezza M, Mustacchi G, Casadei Gardini A, Del Mastro L, De Matteis A,

Riccardi F, Adamo V, Aitini E, Amoroso D, Marchetti P, Gori S, Carrozza F,

Maiello E, Giotta F, Dondi D, Venturini M. Biological characterization and

selection criteria of adjuvant chemotherapy for early breast cancer: experience

from the Italian observational NEMESI study. BMC Cancer. 2012 Jun 6;12:216. doi:

10.1186/1471-2407-12-216. PMID: 22672524; PMCID: PMC3433340.

 

125: Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, Rosetti P,

Bravaccini S, Calistri D, Saragoni L, Casadei Gardini A, Ragazzini A, Frassineti

GL, Amadori D, Passardi A. Predictive role of multiple gene alterations in

response to cetuximab in metastatic colorectal cancer: a single center study. J

Transl Med. 2012 May 8;10:87. doi: 10.1186/1479-5876-10-87. PMID: 22569004;

PMCID: PMC3404915.

 

126: Calistri D, Rengucci C, Casadei Gardini A, Frassineti GL, Scarpi E, Zoli W,

Falcini F, Silvestrini R, Amadori D. Fecal DNA for noninvasive diagnosis of

colorectal cancer in immunochemical fecal occult blood test-positive

individuals. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2647-54. doi:

10.1158/1055-9965.EPI-10-0291. PMID: 20929882.